We are the leader in mechanical pulmonary embolism prophylaxis and a provider of complementary products, services and solutions.
We improve patient outcomes.
Bio2 Medical® founded to design, develop, and manufacture innovative medical devices in response to unmet clinical needs.
Pre-clinical studies are completed to verify the design of the Angel® Catheter.
Completed FIM (First in man) Study in Colombia.
First subject enrolled in Angel Catheter Pilot Study
Granted CE Mark for Angel® Catheter for prophylactic use indication.
Published study results of the FIM Study in the Journal of Vascular and Interventional Radiology.
Seminal Angel® Catheter US Patent issued.
Received full approval of US IDE Pivotal Study for Prophylactic Use.
Completed US Early Feasibility Pilot Program Clinical Study (One of 9 companies invited by FDA to participate).
Completed European Post Market Registry w/60 clinical cases completed.
Initiated US Pivotal Investigation of the Angel® Catheter - The Angel® Catheter Clinical Trial.
Published Study Results of the European Registry in the Journal of Trauma and Acute Care Surgery.
Completed enrollment in the pivotal trial investigation of the Angel® Catheter, 18 months ahead of schedule.
Submitted FDA 510(k) application for the Angel® Catheter.
Angel® Catheter receives 510(k) clearance from the United States Food & Drug Administration (FDA)
First Commercial Placements of the Angel® Catheter in the United States